$0.38—Stale · unknown old
NYSE • Last print unknown ago
$0.38—Stale · unknown old
Isoray, Inc. specializes in innovative brachytherapy products for cancer treatment, particularly its proprietary Cesium-131 isotope. The company primarily operates in the U.S. market, targeting oncology centers and hospitals, which positions it uniquely in the niche medical device sector focused on radiation therapy.
Isoray generates revenue through the sale of its Cesium-131 brachytherapy seeds, which are used in localized cancer treatments. The company benefits from a unique competitive advantage due to its proprietary isotope technology, which offers improved efficacy and reduced side effects compared to traditional therapies.
FDA approvals for new brachytherapy products
Partnerships with oncology centers for expanded distribution
Trends in cancer treatment protocols favoring localized therapies
Changes in reimbursement policies affecting hospital purchasing decisions
Regulatory changes impacting medical device approvals
Technological disruption from alternative cancer therapies
Emergence of new competitors in the brachytherapy market
Potential for larger medical device companies to enter the market
Negative operating cash flow impacting liquidity
High reliance on a single product line for revenue
moderate - Demand for cancer treatment can be somewhat insulated from economic cycles, but overall healthcare spending is linked to GDP growth.
Interest rates can impact Isoray's cost of capital for R&D investments and operational financing, potentially affecting growth initiatives and valuation multiples.
minimal - The company has low debt levels, reducing sensitivity to credit market fluctuations.
growth - Investors may be attracted due to potential upside from innovative cancer treatment solutions.
high - The stock has shown significant price fluctuations, reflecting the inherent risks in the biotech sector.